These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25980924)

  • 1. Knowledge management in the QbD paradigm: manufacturing of biotech therapeutics.
    Herwig C; Garcia-Aponte OF; Golabgir A; Rathore AS
    Trends Biotechnol; 2015 Jul; 33(7):381-7. PubMed ID: 25980924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roadmap for implementation of quality by design (QbD) for biotechnology products.
    Rathore AS
    Trends Biotechnol; 2009 Sep; 27(9):546-53. PubMed ID: 19647883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality by design (QbD) approaches in current pharmaceutical set-up.
    Mishra V; Thakur S; Patil A; Shukla A
    Expert Opin Drug Deliv; 2018 Aug; 15(8):737-758. PubMed ID: 30044646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementing quality by design for biotech products: Are regulators on track?
    Luciani F; Galluzzo S; Gaggioli A; Kruse NA; Venneugues P; Schneider CK; Pini C; Melchiorri D
    MAbs; 2015; 7(3):451-5. PubMed ID: 25853461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-based Process Development of Biosimilars as Part of the Quality by Design Paradigm.
    Zalai D; Dietzsch C; Herwig C
    PDA J Pharm Sci Technol; 2013; 67(6):569-80. PubMed ID: 24265299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality by Design (QbD)-Based Process Development for Purification of a Biotherapeutic.
    Rathore AS
    Trends Biotechnol; 2016 May; 34(5):358-370. PubMed ID: 26879188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knowledge management in a waste based biorefinery in the QbD paradigm.
    Rathore AS; Chopda VR; Gomes J
    Bioresour Technol; 2016 Sep; 215():63-75. PubMed ID: 27090404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raman spectroscopy as a process analytical technology for pharmaceutical manufacturing and bioprocessing.
    Esmonde-White KA; Cuellar M; Uerpmann C; Lenain B; Lewis IR
    Anal Bioanal Chem; 2017 Jan; 409(3):637-649. PubMed ID: 27491299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Knowledge Management in Development and Lifecycle Management of Biopharmaceuticals.
    Rathore AS; Garcia-Aponte OF; Golabgir A; Vallejo-Diaz BM; Herwig C
    Pharm Res; 2017 Feb; 34(2):243-256. PubMed ID: 27785590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latent variable modeling to assist the implementation of Quality-by-Design paradigms in pharmaceutical development and manufacturing: a review.
    Tomba E; Facco P; Bezzo F; Barolo M
    Int J Pharm; 2013 Nov; 457(1):283-97. PubMed ID: 24016743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Quality by design approaches for pharmaceutical development and manufacturing of Chinese medicine].
    Xu B; Shi XY; Wu ZS; Zhang YL; Wang Y; Qiao YJ
    Zhongguo Zhong Yao Za Zhi; 2017 Mar; 42(6):1015-1024. PubMed ID: 29027410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidance for performing multivariate data analysis of bioprocessing data: pitfalls and recommendations.
    Rathore AS; Mittal S; Pathak M; Arora A
    Biotechnol Prog; 2014; 30(4):967-73. PubMed ID: 24778085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knowledge management in secondary pharmaceutical manufacturing by mining of data historians-A proof-of-concept study.
    Meneghetti N; Facco P; Bezzo F; Himawan C; Zomer S; Barolo M
    Int J Pharm; 2016 May; 505(1-2):394-408. PubMed ID: 27016500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality by design in pharmaceutical manufacturing: A systematic review of current status, challenges and future perspectives.
    Grangeia HB; Silva C; Simões SP; Reis MS
    Eur J Pharm Biopharm; 2020 Feb; 147():19-37. PubMed ID: 31862299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality cell therapy manufacturing by design.
    Lipsitz YY; Timmins NE; Zandstra PW
    Nat Biotechnol; 2016 Apr; 34(4):393-400. PubMed ID: 27054995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns.
    del Val IJ; Kontoravdi C; Nagy JM
    Biotechnol Prog; 2010; 26(6):1505-27. PubMed ID: 20665659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Process analytical technology (PAT) for biopharmaceutical products.
    Rathore AS; Bhambure R; Ghare V
    Anal Bioanal Chem; 2010 Sep; 398(1):137-54. PubMed ID: 20480150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review on current downstream bio-processing technology of vaccine products.
    Li M; Qiu YX
    Vaccine; 2013 Feb; 31(9):1264-7. PubMed ID: 23313813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategic funding priorities in the pharmaceutical sciences allied to Quality by Design (QbD) and Process Analytical Technology (PAT).
    Aksu B; De Beer T; Folestad S; Ketolainen J; Lindén H; Lopes JA; de Matas M; Oostra W; Rantanen J; Weimer M
    Eur J Pharm Sci; 2012 Sep; 47(2):402-5. PubMed ID: 22749874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review on the modernization of pharmaceutical development and manufacturing - Trends, perspectives, and the role of mathematical modeling.
    Destro F; Barolo M
    Int J Pharm; 2022 May; 620():121715. PubMed ID: 35367580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.